CANNAINVESTOR Magazine August / September 2017 | Page 163

Officer of ABcann . " The construction timelines at both of our locations position ABcann to become a strong competitor in the existing global medical market and to take advantage of the emerging adult consumer market that is expected to emerge in 2018 .”
ABcann ' s reputation as one of the highest quality , pesticide free , standardized products available today received further validation as the Company has completed its ISO 9001 audit by BSI Group Canada and has been recommended for certification . ABcann remains committed to providing the best growing technique and product standards in the industry . The Company continues to operate under one of the highest quality assurance programs in the world , which includes voluntary external third party testing through RPC , a laboratory services provider in New Brunswick , Canada .
About ABcann Global Corporation ( TSX . V : ABCN ):
ABcann Global Corporation ’ s wholly owned subsidiary , ABcann Medicinals Inc ., was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations , which it received on March 21 , 2014 . It obtained a sales license on December 31 , 2015 . ABcann ’ s flagship facility in Napanee , Ontario utilizes proprietary plant-growing technology , including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process . This approach and the systems in place allow ABcann to produce organically grown and pesticide-free , high-yielding plants , which , in turn , can generate high-quality products that are consistent from batch to batch . ABcann is able to control environmental and nutrient demands , tailor-made for a particular strain of cannabis , without the variation that is typical when producing large quantities in less-controlled , larger rooms and greenhousetype structures . ABcann ’ s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product .
ABcann is expanding capacity its current facility to approximately 30,000 sq ft and concurrently undertaking its expansion into a new 150,000 sq ft facility in Napanee . ABcann is pursuing opportunities in Germany , Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles .
ON BEHALF OF THE BOARD OF DIRECTORS “ Aaron Keay "
Aaron Keay CEO and Director

163